Clinical Trial Update: Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) [Phase 4]

View source ↗

Summary

Phase 4 trial update comparing prefilled syringe versus Smartject device for delivering golimumab in adults with moderate-to-severe ulcerative colitis; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ulcerative Colitis | Phase 4 | Status: COMPLETED | Results posted: 2017-01-09